Vildagliptin

CAT:
804-HY-14291-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Vildagliptin - image 1

Vildagliptin

  • Description:

    Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].
  • Product Name Alternative:

    LAF237; NVP-LAF 237
  • UNSPSC:

    12352005
  • Hazard Statement:

    H302, H315, H319, H335
  • Target:

    Apoptosis; Dipeptidyl Peptidase; Ferroptosis
  • Type:

    Reference compound
  • Related Pathways:

    Apoptosis; Metabolic Enzyme/Protease
  • Applications:

    Metabolism-sugar/lipid metabolism
  • Field of Research:

    Metabolic Disease; Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/Vildagliptin.html
  • Purity:

    99.93
  • Solubility:

    H2O : 50 mg/mL (ultrasonic)
  • Smiles:

    O[C@@]1(C2)C[C@H]3C[C@H](C[C@]2(NCC(N4[C@H](C#N)CCC4)=O)C3)C1
  • Molecular Formula:

    C17H25N3O2
  • Molecular Weight:

    303.40
  • Precautions:

    H302, H315, H319, H335
  • References & Citations:

    [1]Villhauer EB, et al. 1-[[ (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S) -pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46 (13) :2774-89.|[2]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64 (2) :226-35.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    Launched
  • Isoform:

    DPP-4
  • CAS Number:

    274901-16-5